Clinical Trial Update: Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating dabrafenib with or without trametinib in combination with ipilimumab for patients with V600E/K mutation‑positive metastatic or unrese…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)
• ipilimumab (ipilimumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Solid Tumours | Phase 1 | Status: COMPLETED